 |
Vol.63 No.1 contents | Japanese/English |
 | Full Text of PDF (3669K) Article in Japanese |
- Case Report -
Two Cases of Squamous Cell Lung Carcinoma with EGFR Mutations Presenting Poor Outcomes After Osimertinib Treatment
Kento Kono1, Kazuhisa Nakashima1, Takamasa Hotta2, Yukari Tsubata1, Teruaki Iwahashi3, Takeshi Isobe11Division of Medical Oncology & Respiratory Medicine, Department of Internal Medicine, Shimane University Faculty of Medicine, Japan, 2Department of Respiratorology, Shimane Prefectural Central Hospital, Japan, 3Department of Pathology, Shimane University Faculty of Medicine, Japan
Background. EGFR mutations are rarer in squamous cell carcinoma than in adenocarcinoma. The efficacy of osimertinib in treating squamous cell carcinoma with EGFR mutations has therefore not yet been investigated. Cases. (1) A 72-year-old man was diagnosed with postoperative recurrence of lung adenocarcinoma (pT2N2M0, stage IIIA, exon19 del). A biopsy was performed after treatment with afatinib and erlotinib. Simultaneously, squamous cell lung carcinoma manifestation and a T790M mutation were observed. Even after osimertinib administration for two months, the condition of the patient worsened. (2) A 70-year-old woman was diagnosed with squamous cell lung carcinoma (cT3N3M1c, stage IVB, L858R). After osimertinib administration for one month, brain metastasis worsened. Since the primary tumor shrank, whole-brain irradiation was performed, and osimertinib was continued. After three months, the primary tumor also worsened. Conclusion. These findings suggest that the efficacy of osimertinib for squamous cell lung carcinoma might be poor in some cases.
key words: Squamous cell lung carcinoma, EGFR mutation, Osimertinib
Received: July 9, 2022
Accepted: September 9, 2022
JJLC 63 (1): 52-57, 2023
